Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2123 (LINC02123) is a human gene that produces a long intergenic non-coding RNA transcript. As part of the lincRNA class, it is distinguished from other lncRNAs by being transcribed from intergenic regions and not overlapping with protein-coding genes. LINC02123 and related lincRNAs play regulatory roles in gene expression, chromatin architecture, and RNA stability, often with considerable tissue specificity. Recent research highlights LINC02123 as a promising biomarker for lung cancer diagnosis, offering utility in non-invasive diagnostic models, including potential blood-based detection methods. It has been identified as a differentially expressed lncRNA in lung cancer datasets, with its downregulation potentially distinguishing tumor from normal samples. Its mechanisms are largely epigenetic or transcriptional, with no current evidence of peptide-coding potential or direct druggability. The clinical use of LINC02123 is primarily as a diagnostic biomarker rather than a therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2123 (LINC02123).